On June 23, 2023, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2022/2023 Patented Medicines (Notice of Compliance) Regulations, Data Protection (C.08.004.1 of the Food and Drug Regulations), and Certificates of Supplementary Protection (fiscal year ending March 31, 2023). Similar to previous such reports, the report includes information for the last 5 years about the eligibility of patents for listing on the Patent Register, the eligibility of drugs for listing on the Register of Innovative Drugs, Certificates of Supplementary Protection, and related court activity.
For the first time, this report breaks down submissions on “Intellectual Property Hold” to indicate the number of drug submissions that were placed on hold in each fiscal year, and the reason (i.e., patents, data protection, or both). For the 2022/2023 fiscal year, of the 123 submissions placed on Intellectual Property Hold, 83 were as a result of patents, 13 as a result of data protection, and 27 as a result of both patents and data protection.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More -
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More